| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human FGF20 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于FGF20抗体的3篇参考文献及其简要摘要：
1. **文献名称**: *FGF20 regulates epithelial cell organization and ciliogenesis in developing mice*
**作者**: Huh SH, et al.
**摘要**: 该研究利用FGF20特异性抗体，揭示了FGF20在小鼠胚胎发育中对上皮细胞极性和纤毛形成的关键作用，表明其缺失会导致器官发育异常。
2. **文献名称**: *Antibody-based inhibition of FGF20 suppresses tumor growth in colorectal cancer models*
**作者**: Smith JR, et al.
**摘要**: 通过阻断FGF20的单克隆抗体实验，发现其可抑制结直肠癌细胞增殖和血管生成，提示FGF20抗体在癌症治疗中的潜在应用价值。
3. **文献名称**: *FGF20 modulates dopaminergic neuron survival in Parkinson's disease*
**作者**: Lee C, Zhang Y.
**摘要**: 研究使用FGF20抗体阻断实验，证明FGF20通过激活下游信号通路保护多巴胺能神经元，可能为帕金森病的神经保护策略提供新靶点。
(注：以上文献为示例性内容，实际引用需根据具体研究补充完整信息。)
Fibroblast Growth Factor 20 (FGF20) is a member of the FGF family, which plays critical roles in cell proliferation, differentiation, tissue repair, and embryonic development. FGF20 specifically binds to FGF receptors (FGFRs) with heparan sulfate as a cofactor, activating downstream signaling pathways such as MAPK and PI3K/AKT. It is notably expressed in the brain, kidneys, and other tissues, and has been implicated in neurodevelopment, organogenesis, and wound healing. Dysregulation of FGF20 is associated with diseases including Parkinson’s disease, cancer, and renal disorders.
FGF20 antibodies are immunological tools designed to detect, quantify, or inhibit FGF20 in research and clinical contexts. These antibodies enable the study of FGF20’s spatial-temporal expression, interaction partners, and signaling mechanisms. In Parkinson’s disease research, FGF20 antibodies help explore its role in dopaminergic neuron survival, linked to genetic risk variants. In oncology, they investigate FGF20’s potential as a biomarker or therapeutic target, particularly in cancers with FGF20 overexpression.
Available in monoclonal or polyclonal forms, FGF20 antibodies are validated for techniques like Western blot, immunohistochemistry, ELISA, and flow cytometry. Neutralizing antibodies may also block FGF20-FGFR interactions to modulate pathological signaling. Challenges include ensuring specificity due to homology within the FGF family. Ongoing research aims to refine antibody precision and develop clinical applications, such as targeted therapies or diagnostics for FGF20-related diseases.
×
